Treatment of immunological (or related) diseases involves administration of an active agent (I) selected from 37 specific (Z)-3-(1-(substituted amino)-1-phenyl-methylene)-2-indolinones and (4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methyl-piperidin-4-yl-methoxy)-quinazoline, optionally together with various other drugs (II). Treatment of immunological diseases or pathological states having an immunological component involves administration of a pharmaceutical composition containing an indolinone or quinazolinone compound (I), optionally together with at least one other drug (II) selected from non-steroidal antiinflammatories, steroids, disease modifying antirheumatic agents, immunosuppressants, biological reaction modifiers and antiinfective agents. (I) is selected from the following compounds and their tautomers, stereoisomers and salts: (1) (Z)-3-(1-(4-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(methylsulfonylamino)-2-indolinone； (2) (Z)-3-(1-(4-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(ethylsulfonylamino)-2-indolinone； (3) (Z)-3-(1-(4-dimethylaminomethyl)-phenylamino)-1-phenyl-methylene)-5-(ethylsulfonylamino)-2-indolinone； (4) (Z)-3-(1-(4-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(phenylsulfonylamino)-2-indolinone； (5) (Z)-3-(1-(4-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(4-amino-phenylsulfonylamino)-2-indolinone； (6) (Z)-3-(1-(4-pyrrolidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(ethylsulfonylamino)-2-indolinone； (7) (Z)-3-(1-(4-(3-aminopropyl)-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene)-5-(ethylsulfonylamino)-2-indolinone； (8) (Z)-3-(1-(4-(N-(piperidin-1-yl-methylcarbonyl)-N-methylamino)-phenylamino)-1-phenyl-methylene)-5-(phenylsulfonylamino)-2-indolinone； (9) (Z)-3-(1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulfonyl-amino)-phenylamino)-1-phenyl-methylene)-5-(N-methyl-N-phenylsulfonylamino)-2-indolinone； (10) (Z)-3-(1-(4-(N-methyl-N-(piperidin-1-yl-methylcarbonyl)-amino)-ph
